Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer


Published in:
Molecular Cancer Therapeutics

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2021 The Authors; Published by the American Association for Cancer Research.
This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer

Nyree Crawford1, Katie J. Stott1, Tamas Sessler1, Christopher McCann1, William McDaid1, Andrea Lees1, Cheryl Latimer1, Jennifer P. Fox1, Joanne M. Munck2, Tomoko Smyth2, Alpesh Shah2, Vanessa Martins2, Mark Lawler1, Philip D. Dunne1, Emma M Kerr1, Simon S. McDade1, Vicky M. Coyle1, and Daniel B. Longley1

ABSTRACT

Inhibitors of apoptosis proteins (IAPs) are intracellular proteins, with important roles in regulating cell death, inflammation, and immunity. Here, we examined the clinical and therapeutic relevance of IAPs in colorectal cancer. We found that elevated expression of cIAP1 and cIAP2 (but not XIAP) significantly correlated with poor prognosis in patients with microsatellite stable (MSS) stage II and III colorectal cancer treated with 5-fluorouracil (5FU)-based adjuvant chemotherapy, suggesting their involvement in promoting chemoresistance. A novel IAP antagonist tolinapant (ASTX660) potently and rapidly downregulated cIAP1 in colorectal cancer models, demonstrating its robust on-target efficacy. In cells co-cultured with TNFs to mimic an inflammatory tumor microenvironment, tolinapant induced caspase-8–dependent apoptosis in colorectal cancer cell line models; however, the extent of apoptosis was limited because of inhibition by the caspase-8 paralogs FLIP and, unexpectedly, caspase-10. Importantly, tolinapant-induced apoptosis was augmented by FOLFOX in human colorectal cancer and murine organoid models in vitro and in vivo, due (at least in part) to FOLFOX-induced downregulation of class I histone deacetylases (HDAC), leading to acetylation of the FLIP-binding partner Ku70 and downregulation of FLIP. Moreover, the effects of FOLFOX could be phenocopied using the clinically relevant class I HDAC inhibitor, entinostat, which also induced acetylation of Ku70 and FLIP downregulation. Further analyses revealed that caspase-8 knockdown RIPK3-positive colorectal cancer models were sensitive to tolinapant-induced necroptosis, an effect that could be exploited in caspase-8–proficient models using the clinically relevant caspase inhibitor emricasan. Our study provides evidence for immediate clinical exploration of tolinapant in combination with FOLFOX in poor prognosis MSS colorectal cancer with elevated cIAP1/2 expression.

Introduction

Colorectal cancer is the second leading cause of cancer-related deaths in the Western world. In stage IV metastatic disease, 5-year and 10-year overall survival (OS) rates are 6% and 1%, respectively (1). 5-Fluorouracil-based chemotherapy is the mainstay of standard-of-care (SoC) treatment for colorectal cancer in both early and advanced disease. However in early-stage disease, the benefit of fluoropyrimidine monotherapy is limited, with OS gains of less than 5% and 10% to 15% reported for stage II and III disease, respectively, with a small additional survival gain for use in combination with oxaliplatin (2, 3). Improved approaches are therefore urgently needed not only for the treatment of advanced colorectal cancer, but also in the adjuvant disease setting for patients who are destined to relapse but whose disease is resistant to SoC chemotherapy.

Cancer cells are frequently “addicted” to a small number of antiapoptotic proteins that are necessary for their survival. These include the inhibitor of apoptosis proteins (IAPs), cIAP1, cIAP2, and XIAP. XIAP directly binds to, and inhibits the activation of, caspases-3, -7, and -9 (4). cIAP1 and cIAP2 act as E3 ubiquitin ligases at complex I, which is formed following binding of the proinflammatory cytokine, TNFα, to TNF receptor 1 (TNFR1). cIAP1 and cIAP2 polyubiquitinate RIPK1 resulting in the activation of the canonical NFKB signaling pathway, which in turn results in the transcription of antiapoptotic proteins, including cIAP1, cIAP2 and inflammatory cytokines (including TNFα itself) in a prosurvival/inflammatory feedforward loop (5). Complex I dissociates following deubiquitination of RIPK1 to form the death-inducing platform, complex IIa composed of FADD, RIPK1, TRADD, and procaspase-8 (6). In the absence of cIAPs, RIPK1 is not polyubiquitinated, and the cell death inducing platform complex IIb (containing of FADD, RIPK1, and caspase-8) is formed, which can also activate cell death. Hence targeting IAPs have potential to both activate cell death and inhibit antiapoptotic and proinflammatory signaling.

Multiple IAP antagonists, based on the endogenous inhibitor SMAC (second mitochondrial activator of caspases), have been developed and several of these are currently under early-phase clinical evaluation including LCL-161, Xevinapant (Debio 1143), Birinapant (TL32711), APG-1387, and tolinapant (ASTX660). Xevinapant is the most clinically advanced IAP antagonist, currently being evaluated in a phase III combination trial with platinum-based chemoradiotherapy in high-risk head and neck squamous cell carcinoma (NCT04459715), following promising results in a phase II trial (7). Xevinapant is also under investigation in combination with the immune checkpoint inhibitor pembrolizumab in multiple cancers, including a specific metastatic colorectal cancer cohort (NCT03871959). Although the majority of these IAP antagonists have inherent selectivity for cIAP over XIAP, others, including APG-1387 and tolinapant (ASTX660) target cIAP1/2 and XIAP.
Tolipant (Astex Pharmaceuticals) is a novel, non-peptidomimetic IAP antagonist with balanced nanomolar potency against cIAP1/2 and XIAP that was discovered utilizing fragment-based drug design (8). The first-in-human phase I trial of tolinapant indicated a manageable safety profile and had evidence of clinical activity; phase II studies are ongoing (9).

In this study, we assessed the activity of tolinapant in preclinical models of colorectal cancer as a single agent and in combination with both SoC chemotherapeutics and novel therapiesrationally selected on the basis of mechanistic insights.

Materials and Methods

Data analysis

The microsatellite stable (MSS) stage III treated colorectal cancer patient cohort was extracted from the GSE39582 (10) datasets, from the National Center for Biotechnology Information Gene Expression Omnibus, and the expression matrix was processed by collapsing to one probe set per gene using MaxMean from the WGCNA package (11). The IAP mRNA levels were normally distributed, high and low level of expression was determined using a median split. Kaplan–Meier estimators and Cox proportional hazards regression analysis were assessed using the survival and survminer R packages. Tumor cell type profiling based on gene signature method has been performed by xCELL (12). The single-sample gene set enrichment analysis (ssGSEA) method was implemented through GenePattern web tool (13) using the Hallmark gene set molecular signature (14). Heatmaps were generated after mean z-score normalization. Gene level cell expression values were assessed from Cancer Cell Line Encyclopedia, curated by the Broad Institute (15).

Compounds

Tolipant was obtained from Astex Pharmaceuticals. Entinostat, necrosumonamide, and emricasan(IDN-6556) were supplied by Sellckchem. Z-VAD-fmk was purchased from Calbiochem. TNFα was supplied by Prospec. 5-Fluorouracil (5FU) and oxaliplatin were obtained from Belfast City Hospital Pharmacy (Belfast, NI).

In vitro models

LoVo, HCT116, DLD-1, SW620, and HT29 cells were purchased as authenticated stocks from ATCC, and frozen stocks were immediately thawed. All cell lines were screened for mycoplasma and resuspended in 1:1 ratio Matrigel (Corning):Media and cultured in ADF complete media: Advanced DMEM/F12 media (Invitrogen), supplemented with 10 mmol/L HEPES (Sigma), 2 nmol/L L-Glutamine (Invitrogen), N2 supplement (Invitrogen), B27 supplement (Invitrogen), 50 ng/mL recombinant human EGF (Peprotech), and 100 ng/mL recombinant murine Noggin (Peprotech). Organoids were harvested in cell recovery solution (Corning), washed with PBS and resuspended in 1:1 ratio Matrigel (Corning):Media and cultured in complete media.

Measuring diameter of organoids

Organoids were cultured and treated as detailed. Pictures of the organoids were taken using an EVOS XL core cell imaging system (Thermo Fisher Scientific) with 10 x magnification. Diameter of organoids, in arbitrary units (AU), were determined utilizing ImageJ software.

Cell line screen

A total of 36 cell line screen was carried out by Chempartner. Each cell line was tested once in duplicate following incubation with 10 different concentration of tolinapant (0.0005–10 μmol/L) and in combination with TNFα (1 ng/mL) for 72 hours. Cell viability was assessed by CellTitre Glo.

Western blotting

Western Blotting was conducted as described previously (18). Mcl-1 (No. 4572S), XIAP (No. 2042S), BAX (No. 5023S), SMAC (No. 2954), RIPK1 (No. 3493), RIPK3 (No. 13526), MLKL (No. 14993), acetylated lysine (No. 9441L), pMLKL (Ser358; No. 91689), pRIPK3 (Ser227; No. 93654), pRIPK1 (Ser166; No. 65746), and PARP (No. 9542) antibodies were purchased from Cell Signaling Technology. Murine RIP3 (No. 9570S) and pRIP3 (Thr231/Ser232; No. 9170S) were also purchased from Cell Signaling Technology. cIAP1 (No. ALX-803-335-C100), cIAP2 (No. ALX-803-341-C100), and caspase-8 (No. ALX-804-242-C100) antibodies were purchased from Enzo. FLIP (No. AG-20B-0056-C100) antibody was from AdipoGen and hyper-acetylated H4 (No. 06-946) was from Millipore. PADD (No. 556402) antibody was purchased from BD Biosciences, caspase-10 (No. M059-3) from MBL, Ku70 (No. Sc-17789) from Santa Cruz Biotechnology, and β-actin (No. A5316) from Sigma.

siRNA transfections

ON-TARGET plus SMART pool Murine cFLIP siRNA and SCR, cFLIP(L), cFLIP(S), cFLIP(T) and caspase-10 siRNA’s was purchased from Dharmacon. siRNA transfections were carried out with Lipofectamine RNAiMAX (Invitrogen) transfection reagent according to the manufacturer’s instructions. siRNA sequences: SCR: UUCUUCC-GAAGUGUCAGCU, FLIP(L): AACAGGAACTCGCTCTACTTT, FLIP(S): AAGGAAAGCTGGCCGCTCAA, FLIP(T): AAGCGCTG-TGTCTCAAGGAGCA. Ku70 siRNA transfections were carried out as described previously (19).

Quantitative PCR

RNA was extracted using HighPure RNA Isolation kit (Roche) according to the manufacturer’s instructions. cDNA was synthesized using Transcriptor First Strand cDNA synthesis kit (Roche) according to the manufacturer’s instructions. Primer sequences: cFLIP(L): F:CCTAGGAATCTGCCTGACGTTATCGA, RTGGGATATACGCTGACGATGATGATG, FLIP(S): F: ATTTCAGAAGGTCTAGAGTTGAC, R: GCAGCAATCCAAAAAGGAGTGCTCA, 18S: F:GTTGACCCGACACCCCATG, R: CACTGCA-ATCCGTAGTACGG, RIPK3: GCTCCACAGCCGTCAGTCG, TGGGCGACATTACCT, Muirine cFLIP: FGCAAGAGCTTCTCCCA-GAGTCAGCA, RTGGTCTGAGTGCCTACGTG, Murine cFLIP: FGGCAGAATCTCCCAAGGCGGATCGAAGG, RGGGACCTAATCAGGGAAGC.

Cell line generation

HCT116 cells overexpressing cFLIP(S) or cFLIP(L) were generated as described previously (18). HCT116, DLD1, LoVo, HT29, and SW620 caspase-8 CRISPR cell lines were generated by retroviral infection with
pLentiCRISPR with guideRNA AAGTGGACGATCGAGATTG, a kind gift from Galt Lahav. HCT116 and HT29 FADD CRISPR cell lines were generated by retroviral infection with pLentiCRISPR with guideRNA GCGGCCGCGTACGACGATTCG. Cells were clonally selected for complete knockdown by Western blot analysis. HCT116 Caspase10 CRISPR cell lines were generated as described previously (20).

Immunoprecipitations
Caspase-8 and acetylated lysine immunoprecipitations were carried out as described previously (18, 19).

Cell surface flow cytometry
TNFR1 cell surface staining was carried out as described previously (18).

Cell viability assay
Two-dimensional cell viability was assessed using CellTiter-Glo Luminescent Assay (Promega) according to the manufacturer’s instructions. Three-dimensional (3D) cell viability was determined with CellTiter-Glo 3D Cell Viability Assay (Promega), according to the manufacturer’s instructions.

Annexin V/propidium iodide staining
FITC-tagged Annexin V (BD Biosciences), propidium iodide (PI; Sigma), and Hoechst stain (Invitrogen) were used to assess cell death. Annexin V/PI staining was assessed by high content microscopy on an Array Scan XTI microscope (Thermo Fisher Scientific).

In vivo experiments
A total of 2 × 10^5 HCT116, HT29, and DLD-1 cells in PBS/Matrigel (Corning) suspension were implanted single flank into 8- to 10-week-old male BALB/c nude mice. When tumors of approximately 100 mm^3 were established, mice were randomized and treated with vehicle and tolinapant. Tolinapant was administered orally with H2O as a vehicle daily, 1 week on, 1 week off, and 1 week on schedule. All procedures were carried out in accordance with the Animals (Scientific Procedures) Act, 1986 under project licenses PPL 2590b and PPL 2874 and maintained as described previously (21). Tumor volume was assessed using digital calipers, three times a week. Tumor volume was calculated by the following formula: shortest tumor diameter^2 × longest tumor diameter × 0.5.

Statistical analysis
Results were compared using a two-tailed Student t test, *, P < 0.05; **, P < 0.01; and ***, P < 0.001.

Results
Elevated cIAP1 and cIAP2 expression correlates with worse prognosis of patients with stage III MSS with colorectal cancer treated with adjuvant chemotherapy. Analysis of patients with colorectal cancer (10) revealed that elevated expression of cIAP1/BIRC2 (HR, 0.47; P = 0.05) and cIAP2/BIRC3 (HR, 0.34; P = 0.009) [which are normally distributed (Supplementary Fig. S1A)], but not XIAP/XIAP correlated with worse OS in patients with stage III MSS treated with chemotherapy postsurgery (adjuvant chemotherapy; Fig. 1A; Supplementary Fig. S1B), whereas no significant association in stage III patients treated by surgery alone. Although cIAP-1 and cIAP-2 expression were significantly correlated (Pearson r = 0.47, P = 1.3e(-8)), not all cIAP1-high tumors were also cIAP2-high (Fig. 1C, Supplementary Fig. S1C). ssGSEA comparing cIAP1-high or cIAP2-high and -low groups identified significant enrichments for several key inflammatory signaling pathways in both the cIAP1- and cIAP2-high groups, including “TNFα” signaling via NFκB” and other inflammatory pathways (Fig. 1B and C). Consistent with this, the tumors from the cIAP1- and cIAP2-high groups were enriched for the presence of several key immune cell types, with significant enrichment of CD4+ memory T cells, TH2 cells, and M1-polarized macrophages in both groups (Fig. 1D and E). In addition to apoptosis signaling, there was also a significant enrichment for KRAS signaling in both the cIAP1- and cIAP2-high groups (Fig. 1B). IAP expression was not higher in KRAS-mutant tumors (and was not correlated with TP53 or BRAF mutations; Supplementary Fig. S1C and S1D), indicating that the correlations between cIAP1/2 expression and survival (Fig. 1A) are not due to enrichment for KRAS-mutant tumors, which have a worse, but not significantly worse prognosis in this MSS stage III cohort (Supplementary Fig. S1E).

Sensitivity of colorectal cancer cell lines to tolinapant in vitro and in vivo
The analysis of the clinical cohort suggested potential for cIAP1 and cIAP2 as therapeutic targets for improving the efficacy of SoC chemotherapy in MSS stage III disease. We therefore next assessed the cell death inducing activity of the novel IAP antagonist tolinapant by screening a panel of 36 colorectal cancer cell lines alone or in the presence of low concentrations of TNFα (Fig. 2A); to reflect the enrichment for TNFα signaling in the cIAP1/2-high groups (Fig. 2E and C) and the presence of immune cells such as M1 macrophages (Fig. 1D and E), which are rich sources of TNFα (22). In the absence of TNFα, tolinapant had modest growth inhibitory effects across the panel, whereas in the presence of TNFα, a high number of cell lines exhibited significant sensitivity to tolinapant (Fig. 2A). These effects were further assessed in a subset of colorectal cancer cell line models with a range of sensitivities (Supplementary Fig. S2A), each of which expressed all the components of the TNFR1 complex II interactome and XIAP at the protein level (albeit to varying levels; Fig. 2B) as well as cell surface TNFR1 (Fig. 2C). On-target activity of tolinapant, as evidenced by degradation of cIAP1 (the pharmacodynamic biomarker for IAP antagonists), was confirmed at nM potency in all five models (Fig. 2D; Supplementary Fig. S2B); whereas cIAP2 was also down-regulated (albeit to a lesser extent than cIAP1) by tolinapant in three of five models. XIAP was unaffected, consistent with the expected effects of IAP antagonists which disrupt XIAP’s protein–protein interactions with caspases-3, -7, and -9, but do not typically cause XIAP degradation (23). Downregulation of cIAP1 in response to tolinapant, which is a result of triggering its autoubiquitination and degradation via the proteasome (24), was found to be rapid and sustained (Supplementary Fig. S2C). Loss of IAPs has been widely reported to result in the formation of the cell death platform, complex II. In the presence of TNFα, tolinapant indeed promoted the formation of complex II as evidenced by the interaction of caspase-8 with RIP1K1; this was also detected in response to tolinapant alone in three of five models. HCT116, HT29 and LoVo cells albeit to a much lower level than in response to tolinapant/TNFα (Fig. 2E; Supplementary Fig. S2D).

In agreement with the cell line screen, significant cell death measured by Annexin V/PI flow cytometry, was observed in response to
Tolinapant in the presence of TNFα in the HCT116 model (Fig. 2F). Similar results were observed in the HT29 model, albeit the extent of cell death at 24 hours was less; however, lower levels of cell death were observed in the DLD-1 model despite complex II formation (Fig. 2E). In the in vivo setting, we hypothesized that murine TNFα (as well as xenograft-derived human TNFα) could potentially drive complex II formation as murine TNFα can bind the human TNFR1. Moreover, IAP antagonists have been reported to promote production of TNFα by monocytic cells (25). Significant albeit limited retardations of tumor growth were observed in HCT116 and HT29 xenografts but not DLD-1, results which were in line with the relative in vitro sensitivity of these models (Fig. 2G).

Tolinapant enhances sensitivity to SoC chemotherapy

Having established the effects of tolinapant/TNFα combinations, we next evaluated whether the addition of tolinapant could increase sensitivity to SoC chemotherapy FOLFOX (5-fluorouracil plus oxaliplatin). Statistically significant enhancement of FOLFOX-induced...
Figure 2.
Sensitivity of colorectal cancer cell lines to IAP inhibitor, tolinapant. A, Cell viability assay in 36 colorectal cancer cell line panel following 72 hours treatment with tolinapant (tolin; 10-point assay 0.0005–10 μmol/L) alone and in combination with TNFα (1 ng/mL), represented as relative activity area (%), calculated as (experimental AUC/max AUC possible). Cell lines categorized as sensitive to tolinapant/TNFα are highlighted in green, intermediate in white, and resistant in orange. B, Western blot analysis of basal expression of FLIP(L), FLIP(S), Mcl-1, cIAP1, cIAP2, XIAP, BAX, SMAC, RIPK1, FADD, procaspase-8, procaspase-10, RIPK3 and MLKL and β-actin in a panel of colorectal cancer cell lines. C, Cell surface expression of TNFR1 in DLD1, SW620, LoVo, HT29, and HCT116 cell lines, represented as % of TNFR1-positive cells compared with an IgG isotype control. D, Western blot analysis of cIAP1, cIAP2, XIAP, and β-actin in HCT116, HT29, and DLD-1 cells following treatment with 1 μmol/L, 100 nmol/L, 10 nmol/L, 1 nmol/L, and 0.1 nmol/L tolinapant for 24 hours. E, Western blot analysis of RIPK1 and procaspase-8 following immunoprecipitation of caspase-8 from HCT116, HT29, and DLD-1 cells treated with 1 ng/mL TNFα, 1 μmol/L tolinapant and a combination of TNFα/tolinapant for 3 hours in the presence of 20 μmol/L Z-VAD-fmk. An IgG isotype control was used as a control. F, Annexin V/PI analysis in HCT116, HT29, and DLD-1 cells following treatment with 1 ng/mL TNFα, 1 μmol/L tolinapant, or a combination of TNFα/tolinapant for 24 hours. G, Tumor volume (mm³) in HCT116, HT29, and DLD-1 xenograft models treated with vehicle and 16 mg/kg tolinapant. Data show mean tumor volume per treatment group per timepoint ± SEM (HCT116; vehicle n = 10, tolinapant n = 10, HT29; vehicle n = 7, tolinapant n = 7, SW620; vehicle n = 10, tolinapant n = 12). Results were compared using a two-tailed Student t-test, *P < 0.05; **P < 0.01; and ***P < 0.001.
apoptosis was observed in three of five models (HCT116, SW620, and HT29) cotreated with tolinapant alone as well as tolinapant/TNF\(\alpha\) (Fig. 3A and B). Tolinapant alone also significantly enhanced FOLFOX-induced apoptosis in the HCT116 and SW620 models, albeit to a lesser extent than in the tolinapant/TNF\(\alpha\) combination group (Fig. 3A and B). In contrast, the DLD1 model was relatively resistant to the combination (Supplementary Fig. S3A), whereas interestingly, LoVo cells, which were relatively insensitive to the tolinapant/TNF\(\alpha\) combination alone, exhibited significantly increased chemotherapy-induced apoptosis when cotreated with tolinapant alone as well as tolinapant/TNF\(\alpha\) (Supplementary Fig. S3A and S3B). These results were reflected by qualitative assessment of apoptosis by PARP cleavage (Fig. 3B; Supplementary Fig. S3B).

We extended these studies to Apc-null, Kras-mutant(AK) murine colorectal cancer organoid models (16, 17). We also examined the impact of p53 status in these models given the high frequency of its mutation in advanced colorectal cancer. We observed striking combinatorial effects when both p53-proficient “AK” and p53-deficient “AKP” organoids were cotreated with FOLFOX and tolinapant/TNF\(\alpha\) (Fig. 3C and D). CIAPI1 expression was similar in the two organoid models, and tolinapant effectively targeted murine CIAPI1 (Fig. 3E).

Taking the AKP model into the in vivo setting in immune-competent syngeneic mice, we found that the combination treatment of FOLFOX/tolinapant resulted in significant tumor regression compared with the individual treatments (Fig. 3F), and in vivo on-target activity of tolinapant was confirmed (Fig. 3G; Supplementary Fig. S3C).

**FLIP downregulation in response to FOLFOX sensitizes colorectal cancer cells to tolinapant**

We and others have previously demonstrated the importance of the caspase-8 paralog and regulator FLIP/CFLAR as a key mediator of resistance to IAP inhibitors in multiple cancers (18, 21). Notably, protein expression of the short FLIP splice form (FLIP(S)) and XIAP were significantly reduced following FOLFOX treatment in all five models; FLIP(L) was also downregulated in each model at one time-point at least, although to a lesser extent than FLIP(S) (Fig. 3B; Supplementary Fig. S3B). FLIP(L) was also found to be reduced in response to FOLFOX in several tumors in the in vivo AKP experiment (Supplementary Fig. S3D). As tolinapant is active against CIAPI (8), we hypothesized that the impact of FOLFOX on FLIP was more likely to be responsible for the enhanced effects of tolinapant in FOLFOX-treated colorectal cancer cells, particularly in the HCT116 and SW620 KRAS mutant models where FLIP downregulation and the extent of synergy were most marked. Moreover, high FLIP mRNA expression corresponded with resistance to tolinapant/TNF\(\alpha\) in the extended cell line panel (Figs. 2A and 4A), further supporting the importance of FLIP in modulating response to tolinapant in colorectal cancer cells. Somewhat surprisingly, models with high caspase-8 mRNA expression were also more resistant to tolinapant/TNF\(\alpha\), although this can be explained, at least in part, by the close correlation between caspase-8 and FLIP mRNA expression which are encoded on the same genomic locus (Fig. 4A). Consistent with a role for FLIP in mediating resistance to tolinapant/TNF\(\alpha\), RNAi-mediated downregulation of FLIP significantly enhanced the induction of apoptosis by tolinapant/TNF\(\alpha\) in all but the LoVo model as assessed in short-term cell death (Fig. 4B) and longer-term cell viability (Fig. 4C) assays; moreover, these results were confirmed qualitatively by Western blot analysis of PARP cleavage (Fig. 4D; Supplementary Fig. S3E).

Together, these results indicate that FLIP acts as a key mediator of resistance to tolinapant in colorectal cancer cells, consistent with downregulation of FLIP being a major contributor to the enhanced efficacy of tolinapant in FOLFOX-treated cells. To formally assess this, we made use of HCT116 cell line models stably expressing retroviral transgenes encoding either FLIP(L), FLIP(S), or a FADD binding deficient mutant form of FLIP(S) (F114A) compromised in its ability to inhibit procaspase-8 homodimerization (Fig. 5A; ref. 26). Overexpression of FLIP(S), the more potent caspase-8 inhibitory form of FLIP (27), significantly abrogated apoptosis induced by FOLFOX in combination with tolinapant/TNF\(\alpha\) (Fig. 5B), whereas expression of the FLIP(S) trans-gene failed to protect HCT116 cells from apoptosis induced by FOLFOX in combination with tolinapant/TNF\(\alpha\) (likely due in part to the relatively small degree of FLIP(L) overexpression in this model; Fig. 5A). Overexpression of the F114A mutant of FLIP(S) failed to confer protection, indicating that it is FLIP(S)’s interaction with FADD that blocks caspase-8–dependent apoptosis in response to FOLFOX combination with tolinapant/TNF\(\alpha\).

Compared with a HCT116 caspase-8 CRISPR knockout (KO) model in which cell death induced by the tolinapant/TNF\(\alpha\)-FOLFOX combination was almost completely abrogated (Fig. 5C and D), significant cell death was still observed in response to the combination in the FLIP(S) overexpression model (Fig. 5B), suggesting that additional factors other than FLIP downregulation contribute to the effects of the combination. The role of caspase-8–8’s other paralog caspase-10/ CasP10 as a regulator of apoptotic cell death is controversial, with both pro- and antiapoptotic roles described previously (20, 28, 29). We found that cotreatment of HCT116 cells with tolinapant/TNF\(\alpha\)-FOLFOX dramatically reduced the levels of procaspase-10 expression (Fig. 5C). Loss of the pro-form of procaspases can be indicative of activation and suggested participation of procaspase-10 in the overall mechanism of apoptosis induction. However, in the absence of procaspase-8, relatively little decrease of procaspase-10 was observed (Fig. 5C). In contrast to the protective effect of loss of procaspase-8, we found that rather than attenuating cell death, siRNA-mediated downregulation of procaspase-10 significantly enhanced PARP cleavage and executioner caspase activation in response to tolinapant/TNF\(\alpha\) (Fig. 5E and F). To further investigate this, we generated CRISPR models with either procaspase-8, procaspase-10 or both knocked out (Fig. 5G). In agreement with the RNAi results, KO of procaspase-10 enhanced apoptosis induction in response to tolinapant/TNF\(\alpha\) in the presence of caspase-8 (Fig. 5G). These results reveal a heretofore unreported role for procaspase-10 in inhibiting the apoptotic response to IAP antagonists. Furthermore, this is consistent with SW620 cells, which exhibit the lowest levels of procaspase-10 expression, being the most sensitive to tolinapant/TNF\(\alpha\), while DLD-1 cells, with the highest levels of procaspase-10, are highly resistant (Fig. 2B and F). Indeed, siRNA-mediated depletion of procaspase-10 also enhanced the sensitivity of DLD-1 cells to tolinapant/TNF\(\alpha\) (Fig. 5E).

Mechanistically, the effects of FOLFOX on FLIP expression were not due to suppression of transcription; mRNA expression of FLIP(S) was upregulated at 24 hours by approximately twofold and FLIP(L) was upregulated by approximately fivefold at 48 hours (Supplementary Fig. S4A). Inhibition of histone deacetylases (HDAC) has previously been reported by us and others to result in reduced expression of both splice forms of FLIP, at transcriptional and posttranslational levels and augment cell death induced by activators of extrinsic cell death (19, 20). It was therefore notable that FOLFOX treatment downregulated expression of the class I HDACs (HDAC-1, HDAC-2, and HDAC-3) as did tolinapant/TNF\(\alpha\) (Fig. 5H). Moreover, downregulation of HDAC1 and HDAC3 by both FOLFOX and tolinapant/TNF\(\alpha\) was attenuated in CASP8-null cells, indicating that these effects are caspase-8–dependent and therefore potentially consequences of caspase-8 activation. In contrast, FOLFOX-mediated downregulation
Figure 3.
Tolinapant synergizes with chemotherapy. A, Annexin V/PI analysis in HCT116, SW620, and HT29 cells treated with 1 ng/mL TNFα, 1 μmol/L tolinapant, or a combination of tolinapant/TNFα in the presence and absence of 5 μmol/L 5FU and 1 μmol/L oxaliplatin (OX) for 72 hours. B, Western blot analysis of PARP, cIAP2, cIAP1, XIAP, FLIP(L), FLIP(S), and β-actin in HCT116, SW620, and HT29 cells treated with 5 μmol/L 5FU and 1 μmol/L oxaliplatin (FOLFOX), 1 μmol/L tolinapant and a combination of FOLFOX/tolinapant (COMBO) for 24 and 48 hours. C, Pictures from AKP and AK organoids treated with 1 μmol/L tolinapant/1 ng/mL TNFα (tolin/TNF), 5 μmol/L 5FU and 1 μmol/L oxaliplatin (FF) or combination (COMBO) for 72 hours. Diameter in AU from AKP (n = 75 for each treatment group) and AK (n = 75 for each treatment group) organoids treated with 1 μmol/L tolinapant/1 ng/mL TNFα (tolin/TNF), 5 μmol/L 5FU and 1 μmol/L oxaliplatin (FOLFOX) or combination (COMBO) for 72 hours. D, Cell viability assays in AKP and AK organoids treated with 1 μmol/L tolinapant/1 ng/mL TNFα (tolin/TNF), 5 μmol/L 5FU and 1 μmol/L oxaliplatin (FOLFOX) or combination (COMBO) for 72 hours. E, Western blot analysis of basal expression of cIAP1, p53, and β-actin in AK and AKP organoids. Western blot analysis of cIAP1 and β-actin in AK and AKP organoids treated with 1 μmol/L tolinapant for 24 hours. F, Tumor volume (mm³) of AKP organoids transplanted into C57BL/6 mice treated with vehicle (n = 3), 5FU (10 mg/kg) + oxaliplatin (1 mg/kg; FOLFOX; n = 4), tolinapant (16 mg/kg; n = 4) and combination (n = 4). Data show mean tumor volume per treatment group per timepoint ± SEM. G, Densitometry from Western blot analysis of cIAP1 normalized to β-actin in AKP organoids transplanted into C57BL/6 mice and treated with vehicle (n = 3), 5FU (10 mg/kg) + oxaliplatin (1 mg/kg; FOLFOX; n = 4), tolinapant (16 mg/kg; n = 4), and combination (n = 3). Results were compared using a two-tailed Student t test, *P < 0.05; **P < 0.01; and ***P < 0.001.
of HDAC2 was caspase-8–independent, suggesting that this is an event upstream of caspase-8 activation. We previously found that HDAC inhibitors modulate FLIP expression at the posttranscriptional level by inducing acetylation of Ku70, a central component of the non-homologous end-joining (NHEJ) DNA damage repair pathway (19). In its nonacetylated form, Ku70 binds FLIP and inhibits its proteasomal degradation; however, its acetylation in response to HDAC inhibitors blocks this interaction, leading to FLIP degradation. It was therefore notable that FOLFOX caused significant Ku70 acetylation (Fig. 5I). Moreover, silencing Ku70 not only resulted in decreased levels of FLIP, it also enhanced apoptosis induced by tolinapant/TNFα as assessed by PARP cleavage and executioner caspase activation (Fig. 5J). In further support of this mechanism, we also found that entinostat, a class I–selective HDAC inhibitor, potently induced...

Figure 4.
Role of FLIP in determining sensitivity to tolinapant. A, Expression of caspase-8 and FLIP mRNA [log2 (TPM (transcripts per million) + 1)] in colorectal cancer cell lines categorized as sensitive or resistant to tolinapant/TNFα in the cell line screen in Fig. 2A. B, Annexin V/PI analysis in HCT116, SW620, HT29, DLD-1, and LoVo cells transfected with control (SCR) and FLIP(T) siRNA for 24 hours prior to treatment with 1 μmol/L tolinapant and 1 ng/mL TNFα for a further 24 hours. C, Cell viability assays in HCT116, SW620, HT29, DLD-1, and LoVo cells transfected with control (SCR) and FLIP(T) siRNA for 6 hours prior to treatment with 1 μmol/L tolinapant and 1 ng/mL TNFα for a further 24 hours. D, Western blot analysis of PARP, FLIP(L), FLIP(S), cIAP1, and β-actin and in HCT116, SW620, and HT29 cells transfected with control (SCR) and FLIP(T) siRNA for 24 hours prior to treatment with 1 μmol/L tolinapant and 1 ng/mL TNFα for a further 24 hours. Results were compared using a two-tailed Student t test, *P < 0.05; **P < 0.01; and ***P < 0.001.
Figure 5.
Mechanism of chemotherapy-induced sensitization to tolinapant. **A,** Western blot analysis of FLIP(L), FLIP(S), and β-actin in HCT116 cells retrovirally overexpressing pbabe empty vector (EV), pbabe FLIP(S), pbabe FLIP(S) F114A, and pbabe FLIP(L). **B,** Annexin V/PI analysis of in HCT116 cells retrovirally overexpressing pbabe empty vector (EV), pbabe FLIP(S), pbabe FLIP(S) F114A, and pbabe FLIP(L) following treatment with 1 μmol/L tolinapant/1 ng/mL TNFα, 5 μmol/L 5FU, and 1 μmol/L oxaliplatin (FOLFOX) or combination for 48 hours. **C,** Western blot analysis of PARP, cIAP1, FLIP(L), FLIP(S), procaspase-8, procaspase-10, and β-actin in HCT116 WT and HCT116 caspase-8 KO cells treated with 1 μmol/L tolinapant/1 ng/mL TNFα (tolin/TNFα), 5 μmol/L 5FU and 1 μmol/L oxaliplatin (FF) or combination for 48 hours. **D,** Annexin V/PI analysis in HCT116 WT and HCT116 caspase-8 KO cells treated with 1 μmol/L tolinapant/1 ng/mL TNFα, 5 μmol/L 5FU, and 1 μmol/L oxaliplatin (FOLFOX) or combination for 72 hours. **E,** Western blot analysis of procaspase-10, PARP, cleaved caspase-3, FLIP(L), FLIP(S), cIAP1, and β-actin in HCT116 and DLD1 cells transfected with control (SCR) and caspase-10 (siC10) siRNA for 24 hours prior to treatment with 1 μmol/L tolinapant and 1 ng/mL TNFα (tolin/TNFα) for a further 24 hours. **F,** Caspase-3/7 activity assay in HCT116 cells transfected with control (SCR) and caspase-10 siRNA (siC10) for 24 hours prior to treatment with 1 μmol/L tolinapant and 1 ng/mL TNFα for a further 24 hours. **G,** Western blot analysis of HDAC1, HDAC2, HDAC3, and β-actin in HCT116 WT and HCT116 caspase-8 KO cells treated with 1 μmol/L tolinapant/1 ng/mL TNFα, 5 μmol/L 5FU, and 1 μmol/L oxaliplatin (FOLFOX) or combination for 48 hours. **H,** Western blot analysis of Ku70, FLIP(L), FLIP(S), and β-actin in HCT116 WT and HCT116 caspase-8 KO cells treated with 1 μmol/L tolinapant/1 ng/mL TNFα (tolin/TNFα), 5 μmol/L 5FU, and 1 μmol/L oxaliplatin (FOLFOX) for 24 hours. An IgG isotype control was used as a control. **I,** Western blot and caspase-3/7 activity analyses of Ku70, FLIP(L), FLIP(S), procaspase-10, PARP, cIAP1, cIAP2, XIAP, and β-actin and in HCT116 cells transfected with control (SCR) and Ku70 siRNA (siKU70) for 24 hours prior to treatment with 1 μmol/L tolinapant and 1 ng/mL TNFα (tolin/TNFα) for a further 24 hours.
acetylation of Ku70 (Supplementary Fig. S4B) downregulated FLIP(L) and FLIP(S) (Supplementary Fig. S4C) and sensitized all but the LoVo cells to tolinapant/TNFα (Supplementary Fig. S4D); this is consistent with the latter’s lack of sensitization by FLIP silencing (Fig. 4B; Supplementary Fig. S3E). Moreover, HCT116 and DLD-1 cells caspase-8 KO cells were resistant to cell death induced by the entinostat/tolinapant/TNFα (Supplementary Fig. S4E) as was an HCT116 FADD-deficient model (Supplementary Fig. S4F). In addition, overexpression of either FLIP(L) or FLIP(S) abrogated the sensitization of HCT116 cells to tolinapant/TNFα by entinostat (Supplementary Fig. S4G), indicating that entinostat-mediated sensitization is more FLIP dependent than FOLFOX-mediated sensitization, which was only inhibited by the more highly overexpressed and more potent caspase-8 inhibitor FLIP(S) (Fig. 5B).

**Loss or inhibition of caspase-8 leads to necroptosis induction in response to tolinapant/TNFα in RIPK3 positive colorectal cancer models**

Entinostat was also shown to sensitize HT29 wild-type (WT) cells to tolinapant/TNFα (Fig. 6A); however, unlike the rescue that was observed in HCT116 and DLD-1 cells (Supplementary Fig. S4E), CRISPR KO of caspase-8 in HT29 cells resulted in enhanced sensitivity to tolinapant/TNFα (and tolinapant alone), even in the absence of entinostat (Fig. 6A). This effect was abrogated by the necroptosis inhibitor, necrosulfonamide, but not by the pan-caspase inhibitor zVAD, indicating that it is due to the induction of necroptosis rather than apoptosis (Supplementary Fig. S5A). Necroptosis is a proinflammatory, RIPK1/RIPK3-dependent, but caspase-independent form of programmed cell death. Of the human colorectal cancer cell lines profiled for tolinapant activity, only HT29 and SW620 cells expressed RIPK3 at the protein (Fig. 2B) and mRNA levels (Supplementary Fig. S5B). Necroptosis induction was also observed in SW620 CASP8 KO cells (Supplementary Fig. S5C). These results were further supported by Western blot analyses, which demonstrated phosphorylation of RIPK1, RIPK3 and the effector of necroptosis, MLKL (mixed lineage kinase domain-like) in caspase-8-deficient HT29 (Fig. 6B) and SW620 cells (Supplementary Fig. S5D). Moreover, direct assessment of cell death (propidium iodide positivity) further confirmed that the mechanism of cell death induced by tolinapant/TNFα in caspase-8-deficient HT29 (Fig. 6C) and SW620 cells (Supplementary Fig. S5E) was via necroptosis. Furthermore, FADD-deficient HT29 cells were also sensitive to tolinapant/TNFα, a cell death phenotype that was not rescued through inhibition of caspases (Supplementary Fig. S5F).

Notably, the pan-caspase inhibitor zVAD induced necroptotic cell death in response to tolinapant/TNFα in parental HT29 cells (Fig. 6C; Supplementary Fig. S6A), but was less efficient at doing so in SW620 cells (Supplementary Fig. S5C and S5E). zVAD also sensitized AK and AKP mouse organoids to tolinapant/TNFα (Supplementary Fig. S6B). We therefore investigated the potential of caspase inhibition as a combination partner for tolinapant in RIPK3-positive colorectal cancer using emricasan (IDN-6556), a pan-caspase inhibitor already under evaluation in clinical trials in chronic liver disease (30). Pretreatment of HT29 or SW620 cells with emricasan resulted in marked sensitization to necroptosis induced by tolinapant/TNFα (Fig. 6D and E; Supplementary Fig. S6C–S6E) and was considerably more efficacious than zVAD. These findings were mirrored in the AK and AKP mouse organoid models, where significant combinatorial effects and necroptotic pathway activation were also observed (Fig. 6F and G; Supplementary Fig. S6F).

**Discussion**

Colorectal cancer is the second leading cause of cancer deaths in the Western world, with resistance to programmed cell death contributing to treatment failure. Multiple IAPs are overexpressed in colorectal cancer and correlate with therapy resistance and poorer survival rates, making them an attractive target for cancer therapy (31, 32). Here, we report that stage III chemotherapy-treated patients with MSS colorectal tumors with elevated expression of cIAP1 or cIAP2 (but not XIAP) have a poor prognosis. This finding makes cIAP1/2-high MSS colorectal cancer a particularly attractive subpopulation for IAP-targeted therapeutics.

Preclinically, IAP antagonists, including tolinapant, synergize with multiple anticancer therapies, including radiotherapy, chemotherapy, TRAIL receptor agonists, and hypomethylating agents as well as showing promise in combination with PD-1/PD-L1 blockade (33, 34). Overall, despite demonstrating potent on-target activity through rapid and sustained downregulation of cIAP1, colorectal cancer cell lines showed a limited response to tolinapant alone, although sensitivity was significantly enhanced in many cell lines in the context of cotreatment with TNFα. This cotreatment reflects the significant enrichment for TNFα signaling in cIAP1/2-high tumors (Fig. 1C) presumably due to elevated levels of immune cells (Fig. 1D) despite these being MSS tumors that are reported to be predominantly immune cold (35). cIAP1/2 are both canonical target genes of NFκB (36), suggesting that elevation of TNFα signaling may be the driver for enhanced IAP expression in these poor prognostic tumors. Moreover, we found that tolinapant/TNFα enhanced cell death induced by FOLFOX, the SoC regimen for colorectal cancer, in several human and mouse colorectal cancer models *in vitro*, with preclinical antitumor activity also demonstrated *in vivo*, where it was well tolerated, suggesting its potential in combination with SoC chemotherapy.

Mechanistically, FOLFOX downregulated expression of FLIP, a pseudoenzyme paralog of caspase-8 leading to enhanced caspase-8–dependent cell death in response to tolinapant. FLIP negatively regulates apoptosis induction from complex II by inhibiting procaspase-8 homodimerization, a prerequisite for the latter’s activation to its apoptosis-inducing catalytic form (37). The caspase-8/FLIP(L) heterodimer [but not the caspase-8/FLIP(S) heterodimer] also has catalytic activity, which can inhibit necroptotic signaling from complex Ila/b through the cleavage and inactivation of RIPK1/3 (38). We and others have previously identified FLIP as a mediator of resistance to IAP antagonist therapy in multiple cancers, including mesothelioma and castrate-resistant prostate cancer (18, 21). Class I HDACs (HDAC1/2/3) have been found to be overexpressed in colorectal cancer and promote resistance to chemotherapy (39). Here, we found that FOLFOX treatment resulted in downregulation of the class 1 HDACs and acetylation of their substrate Ku70, an essential component of the NHEJ DNA damage repair machinery that repairs double-strand breaks, including those induced by DNA-damaging chemotherapy, such as FOLFOX (40). We have previously reported that Ku70 binds to and enhances FLIP stability when in its nonacetylated form (19), a finding corroborated by others. Consistent with this, silencing Ku70 resulted in FLIP downregulation and enhancement of tolinapant/TNFα-induced cell death. Moreover, the oral class 1 HDAC inhibitor, entinostat, which is well tolerated in humans, also acetylated Ku70 and downregulated FLIP expression resulting in sensitization to tolinapant in the majority of colorectal cancer models.

Procaspase-10 shares significant homology with procaspase-8: they are 46% identical in their catalytic domains, and overexpression of procaspase-10 splice forms 10A and 10D has been shown to resensitize...
caspase-8–deficient cells to TRAIL (28). However, caspase-10 has also been shown to inhibit caspase-8 activation by the Fas/CD95 death receptor, supporting earlier studies in which it was shown that the caspase-8/-10 heterodimer is inactive (29, 41). Our mechanistic studies are consistent with an inhibitory role for procaspase-10 in regulating apoptosis signaling from the death complexes induced by tolinapant/TNFα. To our knowledge, this is the first study to identify caspase-10 as an inhibitor of complex IIa/b.

Necroptosis induced by TNFα signaling is a caspase-independent form of programmed cell death, dependent on RIPK1, RIPK3, and...
Necroptosis, unlike apoptosis, results in the activation of inflammatory responses through the release of damage-associated molecular patterns from dying cells, which promote antitumor immunity through recruitment of inflammatory cells, maturation of dendritic cells, and eliciting cross-priming of CD8+ T cells (44, 45). RIPK3 expression is lost in multiple cancers, including many colorectal cancers, and correlates with cancer progression (46, 47). Loss of RIPK3 expression and necroptosis resistance is correlated with BRAF gain-of-function mutations, AXL overexpression, and RIPK3 promoter hypermethylation (48). CRISPR-mediated KO of caspase-8 or FADD in RIPK3-positive colorectal cancer models resulted in dramatic induction of necroptosis by tolinapant/TNFα. Thus, if clinical resistance to FOLFOX/tolinapant combination therapy emerges due to procaspase-8 or FADD mutations, BRAF inhibitors, AXL inhibitors or epigenetic modifying agents that upregulate RIPK3 expression may make these resistant tumor cells sensitive to tolinapant-induced necroptosis.

Emricasan is an orally active caspase inhibitor that is well tolerated in humans. We found that tolinapant and emricasan cotreatment potently activated necroptosis in the presence of TNFα, but only in RIPK3-positive colorectal cancer models. Compared with zVAD, emricasan is a more potent inhibitor of the enzymatic activity of the caspase-8/FLIP(L) heterodimer that cleaves RIPK1 (49). Our data therefore suggest that tolinapant/emricasan combinations may be effective in proinflammatory, RIPK3-positive colorectal cancers.

Multiple IAP antagonists, including tolinapant, are currently in clinical trials, and single-agent clinical response was observed predominantly in lymphoma for tolinapant while responses in solid tumors were more limited (9). Tolinapant was recently granted orphan drug designation for the treatment of patients with T-cell lymphomas. Here, we have highlighted the potential of combining tolinapant with FOLFOX in colorectal cancer. This SoC chemotherapy is the mainstay of treatment in MSS colorectal cancer in the neoadjuvant, adjuvant, and advanced disease settings, hence strategies to overcome treatment resistance are required. There is a particular rationale for considering an oxaliplatin-based SoC combination, as preclinical modeling in other cancer types has demonstrated induction of expression of immunogenic cell death markers and enhanced response to radiation both in vivo (50) and clinically (7) in head and neck cancer. The potential mechanisms by which IAP antagonists may induce antitumor immune effects and hence antitumor activity beyond overcoming tumor cell resistance to apoptosis are under evaluation. While checkpoint inhibitors may seem a rational potential combination partner for IAP antagonists, at present, SoC chemotherapy remains a more attractive treatment option given the failure to date of checkpoint inhibitors alone or in combination with other agents in the immune-cold tumor microenvironment of MSS colorectal cancer. This combination could be particularly beneficial in the treatment of stage III, cIAP1/2-high MSS disease, which, as we have reported here, has a particularly poor prognosis when treated adjuvantly with FOLFOX alone. We have also identified FLIP as an intrinsic resistance mechanism to IAP antagonist therapy in colorectal cancer, the inhibitory effects of which can be overcome (at least in a subset of disease models) by FOLOX treatment and the clinically relevant class 1 HDAC inhibitor, entinostat. Moreover, in RIPK3-positive colorectal cancer, the clinically well-tolerated caspase inhibitor, emricasan induces necrototic cell death. Of note, this may be the preferred mode of cell death in the predominantly immune-cold MSS disease setting due to potent pro-inflammatory effects of necroptosis.

Authors’ Disclosures

J.M. Munck reports personal fees from Astex Pharmaceuticals outside the submitted work. M. Lawler reports grants from Pﬁzer; personal fees from EMD Serono, Roche, BMS, and Carrell Farrar outside the submitted work. V.M. Coyle reports nonfinancial support from Astex Pharmaceuticals during the conduct of this study; personal fees from Servier and other support from Servier outside the submitted work. D.B. Longley reports grants from Astex Pharmaceuticals during the conduct of the study. No disclosures were reported by the other authors.

Authors’ Contributions

N. Crawford: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, investigation, methodology, writing–original draft, project administration, writing–review and editing. K.J. Stott: Conceptualization, data curation, formal analysis, supervision, investigation, methodology, writing–original draft, writing–review and editing. T. Sessler: Data curation, formal analysis, investigation. C. McCann: Investigation. W. McDaid: Investigation. A. Lees: Investigation. C. Latimer: Investigation. J. M. Munck: Investigation. T. Smyth: Investigation. A. Shah: Investigation. V. Martins: Investigation. D.B. Longley: Funding acquisition, writing–review and editing. E.M. Kerr: Investigation, writing–review and editing. S.S. McDade: Conceptualization, formal analysis, supervision, funding acquisition, writing–original draft, writing–review and editing. V.M. Coyle: Conceptualization, funding acquisition, writing–original draft, writing–review and editing. D.B. Longley: Conceptualization, resources, data curation, formal analysis, supervision, funding acquisition, investigation, writing–original draft, project administration, writing–review and editing.

Acknowledgments

Received December 9, 2020; revised February 25, 2021; accepted June 4, 2021; published first August 13, 2021.

References


Molecular Cancer Therapeutics

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer

Nyree Crawford, Katie J. Stott, Tamas Sessler, et al.

Mol Cancer Ther Published OnlineFirst August 13, 2021.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-20-1050

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2021/06/10/1535-7163.MCT-20-1050.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/early/2021/08/13/1535-7163.MCT-20-1050. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.